No Prescription |
 |
 | ||
|
Daktarin Generic Miconazole |
|
| ||
No Prescription » Prescription Drugs 5 » Daktarin Generic Miconazole Daktarin spray is a broad spectrum antifungal product. It treats commom fungal and candidal skin infections and provides a cooling effect as it is sprayed on and dries the instant it contacts the skin. Buy Daktarin Generic Miconazole and other Prescription Drugs 5 products online at Medstore. Buy Online at Medstore - Click Here!
About Daktarin Generic Miconazole: Product Type: Prescription Drugs 5 Daktarin ( Generic Miconazole ) Daktarin (Generic Miconazole) Generic Miconazole 2% Tincture 30mL Cream 90gm(3 x 30gm) Cream 30gm Lotion 90mL(3 x 30mL) Lotion 30mL Powder 30gm Spray Powder 30gm Generic Miconazole Daktarin
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
